Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...

What will Eli Lilly do with all its cash from Mounjaro and Zepbound? What does CEO Dave Ricks think it would take for the company to reach a $1 trillion market capitalization? And how does Ricks ...

Eli Lilly’s CEO Dave Ricks acknowledged the challenges in predicting growth in the rapidly expanding GLP-1RA market. During the conference presentation, he said: “It’s always disappointing to miss ...

SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, even if there were reasons for ...

“While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration of growth for the quarter,” David ...

Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...